195 related articles for article (PubMed ID: 34980260)
1. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.
Jiguet-Jiglaire C; Boissonneau S; Denicolai E; Hein V; Lasseur R; Garcia J; Romain S; Appay R; Graillon T; Mason W; Carpentier AF; Brandes AA; Ouafik L'; Wick W; Baaziz A; Gigan JP; Argüello RJ; Figarella-Branger D; Chinot O; Tabouret E
Acta Neuropathol Commun; 2022 Jan; 10(1):1. PubMed ID: 34980260
[TBL] [Abstract][Full Text] [Related]
2. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
Tabouret E; Boudouresque F; Barrie M; Matta M; Boucard C; Loundou A; Carpentier A; Sanson M; Metellus P; Figarella-Branger D; Ouafik L; Chinot O
Neuro Oncol; 2014 Mar; 16(3):392-9. PubMed ID: 24327581
[TBL] [Abstract][Full Text] [Related]
3. MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.
Tabouret E; Boudouresque F; Farina P; Barrié M; Bequet C; Sanson M; Chinot O
Neuro Oncol; 2015 Aug; 17(8):1174-6. PubMed ID: 26142442
[No Abstract] [Full Text] [Related]
4. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
[TBL] [Abstract][Full Text] [Related]
5. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
Farina P; Tabouret E; Lehmann P; Barrie M; Petrirena G; Campello C; Boucard C; Graillon T; Girard N; Chinot O
J Neurooncol; 2017 May; 132(3):433-437. PubMed ID: 28265824
[TBL] [Abstract][Full Text] [Related]
6. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E; Bertucci F; Pierga JY; Petit T; Levy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; van Laere S; Ueno NT; Toiron Y; Finetti P; Birnbaum D; Borg JP; Viens P; Chinot O; Gonçalves A
Oncotarget; 2016 Apr; 7(14):18531-40. PubMed ID: 26921265
[TBL] [Abstract][Full Text] [Related]
7. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
9. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
10. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
13. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
[TBL] [Abstract][Full Text] [Related]
14. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Schell M; Pflüger I; Brugnara G; Isensee F; Neuberger U; Foltyn M; Kessler T; Sahm F; Wick A; Nowosielski M; Heiland S; Weller M; Platten M; Maier-Hein KH; Von Deimling A; Van Den Bent MJ; Gorlia T; Wick W; Bendszus M; Kickingereder P
Neuro Oncol; 2020 Nov; 22(11):1667-1676. PubMed ID: 32393964
[TBL] [Abstract][Full Text] [Related]
15. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
16. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.
Quillien V; Carpentier AF; Gey A; Avril T; Tartour E; Sejalon F; Campillo-Gimenez B; Vauleon E
Cancer Immunol Immunother; 2019 Jun; 68(6):871-882. PubMed ID: 30830269
[TBL] [Abstract][Full Text] [Related]
17. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.
Kickingereder P; Wiestler B; Graf M; Heiland S; Schlemmer HP; Wick W; Wick A; Bendszus M; Radbruch A
J Neurooncol; 2015 Jan; 121(2):373-80. PubMed ID: 25359396
[TBL] [Abstract][Full Text] [Related]
19. Current role of anti-angiogenic strategies for glioblastoma.
Thomas AA; Omuro A
Curr Treat Options Oncol; 2014 Dec; 15(4):551-66. PubMed ID: 25173555
[TBL] [Abstract][Full Text] [Related]
20. The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
Weller J; Zeyen T; Schäfer N; Schaub C; Potthoff AL; Steinbach JP; Hau P; Seidel C; Goldbrunner R; Tabatabai G; Vatter H; Tzaridis T; Schneider M; Herrlinger U
J Neurooncol; 2023 Sep; 164(3):749-755. PubMed ID: 37787906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
